Oncolytic Vectors Are the Next Wave of Immunotherapies
Oncorus’s armed oHSV selectively infects and replicates in tumor cells, eventually causing tumor cell lysis. Upon lysis, multiple “personalized” tumor antigens and therapeutic immune modulatory payloads are released into the local environment. Neoantigens and immune payloads stimulate and recruit immune cells to destroy local and distant tumors, resulting in a highly effective cancer therapeutic treatment.
Our platform provides potent oncolytic immunotherapies for malignant and benign tumors.
Robust Viral Potency
The Oncorus Next-generation oHSV Pipeline
Robust anti-tumor effect following direct injection of unarmed Oncorus oHSV
Even greater tumor regression with armed Oncorus oHSV
Modest abscopal response observed with unarmed oHSV
Robust abscopal effect observed in non-injected tumor with single immune payload